Ushbu ishga iqtibos qilgan ishlar

3 ta ish

Ish: Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   MaqolaCAR-T cell therapy researchJournal of Hematology & Oncology20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

   Qianqian Huang, Fan Tong, Jiantao Chen +5

   Sharh maqolaNanoplatforms for cancer theranosticsAdvanced Science20250 iqtibos

   ABIABI:AkademIndex/openalex/2025.review-article.000021

3. Pyroptosis-inducing nanomedicines: A dual-mode therapeutic framework for apoptosis-resistant lung cancer

   Qamar Abuhassan, Ghaleb Oriquat, R. Roopashree +5

   MaqolaInflammasome and immune disordersTissue and Cell20260 iqtibos

   ABIABI:AkademIndex/openalex/2026.article.002974